Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor is a phase 1/2, interventional study registered as NCT03093688 by Shanghai Public Health Clinical Center, with a registry enrolment figure of 40 participants, started 2017-03-01 and due to reach its primary completion in 2030-12-31. Interventions recorded: Infusion of iNKT cells and CD8+T cells. Conditions listed: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreas Cancer; Hepatocellular Carcinoma; Gastric Cancer; Renal Cell Carcinoma. Primary outcome: Incidence of adverse events related to the infusion of cells; Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "* Histological or cytologically diagnosis of advanced lung cancer, or advanced gastric cancer, or advanced pancrease cancer, or hepatocellular carcinoma, or advanced colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.